| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 2x1h,1x10min |
| Standardrange | 12.5-200ng/mL |
| Specimen/Volumes | 100µLplasma |
| Substrate/isotope | TMB450nm |
| RegulatoryStatus: | EU:CE |
EnzymeimmunoassayforthequantitativedeterminationofHeparinBindingProteininhumanplasma.HeparinBindingProteinisanewMarkerthathasdemonstratedutilityinidentifyingpatientsatriskofdevelopingseveresepsis.HeparinBindingProtein,alsoknownasCAP37andazurocidin,issynthesisedinneutrophils.Oncereleasedfromactivatedneutrophils,itinducesarearrangementoftheendothelialcellCytoskeleton,resultinginincreasedpermeABIlityoftheendothelium.Atthesiteofinfection,HBPisresponsIBLefortherecruitmentandactivationofmonocytesandotherinflammatorymediators.Itisalsointernalisedbymonocytestoprolongsurvivalandenhancecytokineproduction.HBPthereforedirectlycontributestothemaintenanceandprogressionofinflammation.Apublicationin2009demonstratedthatinfebrilepatientspresentingtotheEmergencyDepartment(ED),thereisaclosecorrelationbetweenincreasedplasmaHBPlevelsandthedevelopmentofseveresepsiswithhypotensionorshock.InthisProspectivestudyof233febrileadultpatientswithsUSPectedsepsis,HeparinBindingProteinwasshowntobethebestpredictorofseveresepsiswithReceiver-operatingcharacteristic(ROC)plotshowinganAreaUnderCurve(AUC)of0.95,exceedingthatofProcalcitonin,IL-6andLactate:
DistributedbyIBLInternational
